Boehringer Ingelheim: New Data Show That More Than 50% of Patients and Carers Struggled to Cope with Challenges of Living with Lung Cancer
INGELHEIM, Germany–(EON: Enhanced Online News)–The Global Lung Cancer Coalition (GLCC) presented, at the 16th World Conference on Lung Cancer (WCLC) in Denver, USA, results of Lung Cancer: We’re Listening, a global campaign, supported by Boehringer Ingelheim. The global survey intended to increase knowledge and understanding of real world challenges facing lung cancer patients and their carers. The data showed 64% of lung cancer patients and 55% of carers identified that daily life challenges, such as emotional and social issues, were more significant than medical care challenges such as diagnosis and treatment planning. The findings of the survey highlight the need for a more holistic approach to lung cancer care. read more
Genentech to Present Data from 15 Medicines Across Its Portfolio of Cancer Immunotherapy and Targeted Medicines During the 2015 European Cancer Congress
SOUTH SAN FRANCISCO, Calif.–(EON: Enhanced Online News)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that data from 138 abstracts will be presented at this year’s European Cancer Congress (ECC) from Sept. 25 – 29 in Vienna, Austria. Results will be presented from several clinical studies that are supporting ongoing regulatory discussions for three investigational medicines across specific types of lung, bladder and skin cancer (alectinib, atezolizumab and cobimetinib, which recently received its first approval in Switzerland where it is marketed as Cotellic®). Building on its large portfolio of approved cancer medicines, these regulatory discussions represent significant progress for Genentech’s pipeline in the fields of cancer immunotherapy and targeted medicines. read more
New Cohorts from CheckMate -012 Assess Optimal Dosing of Opdivo+Yervoy in the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer
PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced updated results from the Opdivo (nivolumab)+Yervoy (ipilimumab) arms in CheckMate -012, a multi-arm Phase 1b trial evaluating Opdivo in patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC). In this study, Opdivo was administered as monotherapy or as part of a combination with other agents, including Yervoy, at different doses and schedules. Results from other cohorts in CheckMate -012 have been previously-unreported. These updated results include findings from the administration of four new dosing schedules of Opdivo+Yervoy (n=148), which resulted in confirmed objective response rates (ORR) ranging from 13% to 39% depending on the administered regimen. Median duration of response was not reached in any of these arms with a median follow-up of 6.2 months to 16.6 months, and median progression-free survival (PFS) ranged from 4.9 months to 10.6 months.
MINNEAPOLIS, Sept. 8, 2015 /PRNewswire-USNewswire/ — DaVita Clinical Research® (DCR®), a specialty contract research organization with services spanning a broad spectrum of drug and device development, announced today its Biospecimen Research Grant Program (BioReG), a grant program to award clinical-trial-quality biospecimens and annotated de-identified data to academic medical centers involved in kidney research. read more
IRIDEX Broadens Global Glaucoma Outreach With Novel Eye Pressure Diagnostic Device
MOUNTAIN VIEW, Calif., Sept. 8, 2015 /PRNewswire/ — IRIDEX Corporation (Nasdaq: IRIX) today announced that it has added a novel intra-ocular pressure (IOP) monitoring device called a tonometer to its suite of commercial products for the global glaucoma market. The new device comes to IRIDEX through a distribution agreement with Icare Finland Plc, a subsidiary of the Revenio Group Corporation, the creator of the tonometer. read more
Impax Announces Resolution of FDA Warning Letter Related to its Hayward Manufacturing Facility
HAYWARD, Calif., Sept. 8, 2015 /PRNewswire/ — Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it received written notice from the United States Food and Drug Administration (FDA) verifying that the Company has successfully addressed all items raised by the FDA in the May 2011 Warning Letter relating to its Hayward, California manufacturing facility.
Leading global health institutions digitize pathology workflows with Philips to enhance disease diagnoses
EINDHOVEN, Netherlands, Sept. 8, 2015 /PRNewswire/ — As the number of trained pathologists decreases while the aging population and complexity of cancer is on the rise, Royal Philips (NYSE: PHG, AEX: PHIA) today announced the growing adoption of its Digital Pathology Solutions by health systems across the globe who are enhancing their operations. Through its IntelliSite Pathology Solution*, Philips enables health care organizations to reinvent the traditional histopathology workflow, enhance efficiency and productivity, and improve the confidence in making diagnosis. read more